Fig. 7: Clinical MIR937 amplification correlates with FBXO16 and ULK1 expression. | Cell Death & Disease

Fig. 7: Clinical MIR937 amplification correlates with FBXO16 and ULK1 expression.

From: MIR937 amplification potentiates ovarian cancer progression by attenuating FBXO16 inhibition on ULK1-mediated autophagy

Fig. 7

a IB analysis of protein levels for ULK1, P62, LC3II/I in MIR937+/+, MIR937+/−, and MIR937−/− OVCAR3 (upper) and A2780 (lower) cells. GAPDH was used as loading control. b IB analysis for comparing FBXO16, ULK1 protein abundances in clinical OV with control samples. Ctrl: normal ovary, MIR937 WT: OV patient samples without amplification of MIR937. MIR937 AMP: OV patient samples with MIR937 amplification. c Representative images for IHC analysis of ULK1 protein in OV patient samples or the normal control, Scale bar: 100 μm. Kaplan–Meier survival analysis of OV patients from GSE26193 dataset grouped by FBXO16 (d) and ULK1 (e) expression. f Kaplan–Meier survival analysis of OV patients grouped by both FBXO16 and ULK1 expression in GSE26193. Similar results were obtained in three independent experiments.

Back to article page